Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.

  title={Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.},
  author={Katherine R. Singleton and Trista K. Hinz and Emily K. Kleczko and Lindsay A. Marek and Jeff W. Kwak and Taylor Harp and Jihye Kim and Aik Choon Tan and Lynn E. Heasley},
  journal={Cancer research},
  volume={75 20},
The FGFR1 is a therapeutic target under investigation in multiple solid tumors and clinical trials of selective tyrosine kinase inhibitors (TKI) are underway. Treatment with a single TKI represents a logical step toward personalized cancer therapy, but intrinsic and acquired resistance mechanisms limit their long-term benefit. In this study, we deployed RNAi-based functional genomic screens to identify protein kinases controlling the intrinsic sensitivity of FGFR1-dependent lung cancer and head… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 4 times. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 13 extracted citations


Publications referenced by this paper.
Showing 1-10 of 31 references

Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014.

Bioorganic & medicinal chemistry letters • 2013
View 6 Excerpts
Highly Influenced

Receptor tyrosine kinase coactivation networks in cancer.

Cancer research • 2010
View 4 Excerpts
Highly Influenced

A phase 1b open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers: preliminary antitumor activity and pharmacodynamic data

PK Paik, R Shen, +3 authors E Kilgour
J Clin Oncol • 2015
View 1 Excerpt

FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2014
View 15 Excerpts

Similar Papers

Loading similar papers…